TV-44749

DRUG2 trials

Sponsors

Teva Branded Pharmaceutical Products R&D LLC

Conditions

Schizophrenia

Phase 1

An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia

CompletedNCT06315283

Teva Branded Pharmaceutical Products R&D LLCSchizophrenia

Start: 2024-03-20End: 2025-09-04Updated: 2026-01-14

Phase 3

A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia

CompletedNCT05693935

Teva Branded Pharmaceutical Products R&D LLCSchizophrenia

Start: 2023-01-24End: 2025-01-27Updated: 2026-03-17

Related Papers

Patient and Healthcare Professional Attitudes and Trial Experiences with a Subcutaneous Long-Acting Injectable Olanzapine (TV-44749) for Schizophrenia Treatment

Advances in Therapy2026-09-15

Population Pharmacokinetic Model-Based Dose Selection of Extended-Release Injectable Olanzapine (TV-44749) for Subcutaneous Use in Phase 3 Clinical Trial in Adults with Schizophrenia.

2026-01-01